The Max Planck Institute for Innovation and Competition is currently conducting a study on Supplementary Protection Certificates in the European Union on behalf of the European Commission. The study aims to include the views and opinions of a wide range of stakeholders including pharmaceutical companies, professional and industry associations as well lawyers, patent attorneys and other interest groups. With this purpose, the Max Planck Institute in collaboration with the German Allensbach Institute is about to distribute a questionnaire-based survey. The survey includes questions on the past experience with the system, general policy considerations, assessment of the present legal rules, as well as some proposals on the potential amendment of the current SPC Regulations. The answers will be collected on an anonymous basis. If you are interested in participating in the survey, please contact the Max Planck Institute at [email protected].